NASDAQ: CAPR - Capricor Therapeutics, Inc.

Доходность за полгода: +320.56%
Сектор: Healthcare

График акции Capricor Therapeutics, Inc.


О компании

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD).

Подробнее
It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Выручка 0.001
EBITDA -0.0078
Число акций ао 0.02678 млрд
P/S 4.65
P/BV 0.6837
EV/EBITDA -0.5307
Цена ао 4.19
ISIN US14070B3096
Сайт https://www.capricor.com
Валюта usd
IPO date 2007-02-13
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Изменение цены за день: -2.45% (21.6)
Изменение цены за неделю: +21.72% (17.31)
Изменение цены за месяц: +359.04% (4.59)
Изменение цены за 3 месяца: +350.21% (4.68)
Изменение цены за полгода: +320.56% (5.01)
Изменение цены за год: +657.91% (2.78)
Изменение цены за 3 года: +472.55% (3.68)
Изменение цены за 5 лет: +704.2% (2.62)
Изменение цены с начала года: +443.04% (3.88)

Недооценка

Название Значение Оценка
P/S 4.73 3
P/BV 5.27 2
P/E 0 0
EV/EBITDA -4.78 0
Итого: 4.38

Эффективность

Название Значение Оценка
ROA, % -37.95 0
ROE, % -98.61 0
Итого: 0

Дивиденды

Название Значение Оценка
Div yield, % 0 0
DSI 0 0
Итого: 0

Долг

Название Значение Оценка
Debt/EBITDA -0.2439 10
Итого: 9.6

Импульс роста

Название Значение Оценка
Доходность Revenue, % 2417.81 10
Доходность Ebitda, % 194.99 10
Доходность EPS, % -58.18 0
Итого: 8

Институционалы Объем Доля, %
Vanguard Group Inc 1165404 3.7
Woodline Partners LP 909542 2.89
Blackrock Inc. 359673 1.14
Geode Capital Management, LLC 316198 1
Susquehanna International Group, LLP 149115 0.47
Renaissance Technologies, LLC 146321 0.46
Northern Trust Corporation 127229 0.4
Osaic Holdings Inc 116550 0.37
State Street Corporation 85224 0.27
Bank Of New York Mellon Corporation 84759 0.27

ETF Доля, % Доходность за год, % Дивиденды, %
ProShares Hedge Replication ETF 0.0008 5.5087969920031 1.47892
iShares Neuroscience and Healthcare ETF 0.2793 21.135856403438 0.03
iShares Micro-Cap ETF 0.03249 35.054312164247 1.54048
iShares Russell 2000 Growth ETF 0.00807 34.028337203241 0.6026
ProShares UltraPro Russell2000 0.00277 81.385281385281 1.47873
Vanguard Russell 3000 ETF 0 35.867021276596 1.43817
Vanguard Russell 2000 Growth ETF 0.01 34.809548656405 0.60264
Vanguard Russell 2000 ETF 0 32.304263853811 1.48801



Руководитель Должность Оплата Год рождения
Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board 120k 1956 (68 лет)
Dr. Linda Marbán Ph.D. Co-Founder, President, CEO & Director 280.62k 1963 (61 год)
Mr. Anthony J. Bergmann M.B.A. CFO & Corporate Treasurer 437k 1986 (38 лет)
Ms. Karen G. Krasney Executive VP, General Counsel & Secretary 426.72k 1953 (71 год)
Dr. Kristi A. H. Elliott Ph.D. Chief Science Officer N/A
Catherine Lee Kelleher Consultant N/A

Адрес: United States, San Diego. CA, 10865 Road to the Cure - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.capricor.com